Brain-derived neurotrophic factor (BDNF) signaling in respiratory disease: Mechanisms, neuroimmune crosstalk, and therapeutic implications

Pulmonary Pharmacology and Therapeutics · Published 2026-07-01 · DOI 10.1016/j.pupt.2026.102435

Authors (2)

Entesar Yaseen Abdo Qaid, Idris Long

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Qaid, E., Long, I. (2026). Brain-derived neurotrophic factor (BDNF) signaling in respiratory disease: Mechanisms, neuroimmune crosstalk, and therapeutic implications. Pulmonary Pharmacology and Therapeutics. https://doi.org/10.1016/j.pupt.2026.102435

Related articles

• Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patients · Pulmonary Pharmacology and Therapeutics · 2026 · Same journal
• Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia · Pulmonary Pharmacology and Therapeutics · 2024 · Same journal
• Prevalence and clinical significance of pre- and post-bronchodilator airflow obstruction in COPD patients · Pulmonary Pharmacology and Therapeutics · 2024 · Same journal
• Drug-drug interactions in vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor-ivacaftor · Pulmonary Pharmacology and Therapeutics · 2025 · Same journal
• Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation · Pulmonary Pharmacology and Therapeutics · 2025 · Same journal
• Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial · Pulmonary Pharmacology and Therapeutics · 2025 · Same journal
• Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment · Pulmonary Pharmacology and Therapeutics · 2026 · Same journal
• Clinical remission at two years post-diagnosis of asthma and its association with clinical outcomes: A retrospective cohort study in asthma patients with maintenance inhaler therapy · Pulmonary Pharmacology and Therapeutics · 2025 · Same journal
• m6A reader IGF2BP2 Mediates Airway Remodeling by Stabilizing Dixdc1 in Asthma Pathogenesis · Pulmonary Pharmacology and Therapeutics · 2026 · Same journal
• Effects of anumigilimab, an anti–G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers · Pulmonary Pharmacology and Therapeutics · 2026 · Same journal